About Genoa Ventures
Genoa Ventures is a venture capital firm founded in 2014. It is primarily based out of San Francisco, United States. As of Jul 2026, Genoa Ventures is an active investor, having invested in 31 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Food and Agriculture Tech. Most recently it participated in the $***** Series B round of Epitel Overall, Genoa Ventures portfolio has seen 1 IPO and 5 acquisitions including key companies like Fortune, Caribou Biosciences and Zymergen. A lot of funds co-invest with Genoa Ventures, with names like Vertical Venture Partners sharing a substantial percentage of its portfolio. Genoa Ventures has team of 10 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 2 more
Portfolio IPOs
Portfolio Soonicorns
Deals in last 12 months
Genoa Ventures' List of Top Investments
Genoa Ventures has a portfolio of 31 companies. Their most notable investments are in Alida Biosciences and Hermes Bioscience.Their portfolio spans across United States, United Kingdom and France. They have invested in Life Sciences, High Tech, Food and Agriculture Tech and 8 other sectors, across stages such as Series A, Series B and 2 more. Here is the list of top investments by Genoa Ventures:
Developer of gene editing technologies for improved tropical crop production. The company focuses on improving crops to be tastier and hardier. It aims to make crops less reliant on pesticides and more resilient to climate change. The company’s technology supports farmers, equipping them against climate change. It helps them to increase their yields.
Key facts about Tropic Biosciences
2. Fortune
Publisher of business news, analysis, rankings, and corporate editorial content. The organization provides reporting on finance, technology, leadership, and lifestyle topics. It produces data-driven lists that assess the performance of corporations and business organizations. Through digital platforms, print media, and multimedia channels, the entity delivers coverage on global economic trends, management strategies, and professional development. The output encompasses market insights, newsletters, and podcasts focused on industry shifts and corporate governance.
Key facts about Fortune
- Location: New York (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Employee Count: 3,090 as on Sep 30, 2026
- Investors: Genoa Ventures, Altair Capital and 2 Others
- Highlight: Acquired
3. Mission Bio
Provider of a single-cell multi-omics platform for genotypic and phenotypic analysis. The company's proprietary Tapestri platform enables the simultaneous detection of analytes, including SNVs, CNVs, and proteins for the precise treatment of cancer. Also, it offers DNA & protein panels, and Pharma Assay Development (PAD) Services.
Key facts about Mission Bio
- Founded Year: 2014
- Location: San Francisco (United States)
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $120M
- Employee Count: 90 as on Sep 30, 2026
- Investors: Mighty Capital, Ally Bridge Group and 29 Others
- Latest Funding Round: Series C, Aug 05, 2025, $*****
- Highlight: Editors' Pick
NanoCellect Biomedical is a developer of molecular diagnostics, and improve personalized medicine. The company offers WOLF Cell Sorter, which uses a closed fluid-path microfluidic cartridge that enables cell sorting, and avoids biohazard and shear stress issues associated with traditional cell sorters. It claims that this technology sorts cells at the highest purity with almost no loss of viability. This technology has downstream applications of gene expression and sequencing. It also used in sorting rare cells such as circulating tumor cells (CTCs) from blood samples.
Key facts about NanoCellect Biomedical
- Founded Year: 2009
- Location: San Diego (United States)
- Stage: Series D
- Total Funding till date: $78.1M
- Employee Count: 21 as on Sep 30, 2026
- Investors: Illumina Ventures, Vertical Venture Partners and 15 Others
- Latest Funding Round: Series D, Jun 29, 2023, $*****
- Highlight: Editors' Pick
5. Epitel
Provider of a wearable EEG recording system for epilepsy monitoring and control. It offers a scalp wearable medical-grade seizure monitoring system. The rechargeable device can be applied to the scalp by an adhesive and can be worn irrespective of time and location. The device is paired via Bluetooth with a mobile application that detects and records seizures. The obtained data can be then used by a doctor to optimize one's treatment and lifestyle.
Key facts about Epitel
- Founded Year: 2007
- Location: Salt Lake City (United States)
- Stage: Series B
- Total Funding till date: $38.5M
- Employee Count: 61 as on Sep 30, 2026
- Investors: Genoa Ventures, Wavemaker 360 and 8 Others
- Latest Funding Round: Series B, Jul 28, 2026, $*****
- Highlight: Editors' Pick
Genoa Ventures' Year-on-Year Investment Trends
Genoa Ventures has invested in 31 companies over the last 11 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 2 investments, while as of Jul 2026, it has made 2 investments in this year. Its most recent first time investment was in Hermes Bioscience and most recent follow-on round was in Epitel.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 2 | 2 |
2025 | 1 | 1 | 2 |
2024 | 1 | 0 | 1 |
2023 | 1 | 0 | 1 |
2022 | 5 | 1 | 6 |
2021 | 3 | 1 | 4 |
2020 | 3 | 2 | 5 |
2019 | 0 | 0 | 0 |
2018 | 2 | 0 | 2 |
2017 | 2 | 0 | 2 |
Genoa Ventures' Investments by Stage
Genoa Ventures has made 13 investments in Series A stage with an average round size of $15.3M, 3 investments in Series B stage with an average round size of $18.8M, 2 investments in Seed stage with an average round size of $1.49M and 1 investment in Series C stage with an average round size of $18.4M.Stage of entry | No. of Investments |
|---|---|
Series A | 13 |
Series B | 3 |
Seed | 2 |
Series C | 1 |
Note: We have considered here, only first round of investments
Genoa Ventures' Investments by Sector
Genoa Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, Food and Agriculture Tech and Consumer. Notably, it has invested in 29 Tech companies, 28 Enterprise (B2B) companies, 8 Software companies and at least 7 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 14 |
High Tech | 6 |
Enterprise Applications | 5 |
Food and Agriculture Tech | 2 |
Consumer | 1 |
Others | 7 |
Note: We have considered here, only first round of investments
Genoa Ventures' Investments by Geography
Genoa Ventures has made most investments in United States (17), followed by France where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 17 |
France | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
Genoa Ventures' recent investments
Genoa Ventures has made 2 investments in 2026 so far - Epitel and Tropic Biosciences.Here are the most recent investments by Genoa Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 28, 2026 | United States | Series B | 4933 | ||
Mar 13, 2026 | United Kingdom | Series C | 9039 | [+9] | |
Nov 18, 2025 | United States | Seed | 3126 | [+1] | |
Jul 10, 2025 | United States | Series B | 4093 | ||
Jun 07, 2024 | United States | Series A | 1477 | [+1] |
IPOs and Publicly Listed companies in Genoa Ventures' Portfolio
1 of Genoa Ventures' portfolio company became public - Caribou Biosciences. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jul 2021 at marketcap of $907MHere are Genoa Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 23, 2021 | Mar 24, 2015 | Series A | 4730 |
Acquired companies in Genoa Ventures' Portfolio
5 companies from Genoa Ventures' portfolio have been acquired. The most recent acquisition was Zymergen in Jul 2022 by Ginkgo Bioworks for $*****.Here are Genoa Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 25, 2022 | - | - | 8501 | |
Jan 21, 2021 | Oct 30, 2018 | Series A | 9623 | |
Jun 04, 2019 | - | - | 6444 | |
Nov 09, 2018 | - | - | 3582 | |
Mar 21, 2016 | - | - | 7506 |
Team profile of Genoa Ventures
Genoa Ventures has a team of 10 members including 3 Partners and 1 Principal located in United States and Switzerland. Genoa Ventures' team does not sit on the board of any company as of now.Here is a list of all team members in Genoa Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | California | - | ||
Partner | Zurich | - | - | |
Partner | San Jose | - | ||
Principal | San Jose | - | - |
Co-investors of Genoa Ventures
Over the past 11 years, 161 investors have co-invested in Genoa Ventures's portfolio companies. This includes funds and angels.
- Invested before Genoa Ventures: HHS, National Science Foundation and 35 others have invested in rounds before Genoa Ventures. There are 4 companies where HHS has invested before Genoa Ventures and 3 companies where National Science Foundation has invested before Genoa Ventures.
- Top Co-investors of Genoa Ventures: 59 investors entered a company along with Genoa Ventures. These include investors like Vertical Venture Partners (4 companies).
- Invested after Genoa Ventures: A total of 65 investors have invested in Genoa Ventures's portfolio after their investments. Top Investors include NIH (2 companies), HHS (2 companies) and Blue Horizon (1 company).
Recent News related to Genoa Ventures
•
Munich’s UVC adds growth stage with €77M, follows Proxima Fusion’s €2B raiseTech Funding News•Mar 13, 2026•Just Climate, Sucden, Five Seasons Ventures, Genoa Ventures and 6 others
•
Hermes Biosciences Raises Seed Funding to Make Extracellular Vesicles a Practical Tool for Precision Medicineintelligence360•Dec 19, 2025•Hermes Bioscience, Vertical Venture Partners, Paladin Capital, Genoa Ventures
•
•
•
Aqtual Raises Over $30M as It Scales Novel cfDNA PlatformBusiness Wire•Jul 10, 2025•Aqtual, Bold Capital Partners, Genoa Ventures, Manta Ray Ventures and 1 other
•
Genoa Ventures Elevates Landon Merrill to Partner, Strengthening Leadership in Science-Driven InvestingBusiness Wire•Oct 22, 2024•Genoa Ventures
•
Alida Biosciences Announces Series A Funding and Early Access Launch of Innovative Products for Epitranscriptomic ResearchBioSpace•Jun 12, 2024•Alida Biosciences, Genoa Ventures, FusionX Ventures, Vertical Venture Partners and 1 other
•
Ionpath Announces Executive Chair Appointment and CEO PromotionBusiness Wire•Dec 06, 2023•Ionpath, Genoa Ventures
•
Charlottesville’s Brightspec Raises Millions To Commercialize Cutting-edge Scientific InstrumentThe Business Journals•Feb 01, 2023•BrightSpec, Genoa Ventures, Arbor Ventures, Arboretum Ventures and 4 others
•
BrightSpec Raises $18.4M in Series C FinancingFinSMEs•Dec 15, 2022•BrightSpec, Genoa Ventures, Arboretum Ventures, Capital Growth Medvest and 2 others
